PREVIOUS
✖
Aducanumab
June 12 , 2021
1147 days
729
0
- Aducanumab (Aduhelm) is the new drug approved by the US Food and Drug Administration (FDA) for treating Alzheimer’s disease.
- It is developed by the company Biogen.
- Alzheimer’s disease causes the accumulation of the debris caused by the breakdown of neurons in the brain.
- This leads to plaque formation.
- Aducanumab is a monoclonal antibody.
- It is designed to reduce the presence of amyloid beta, a protein that forms plaques in the brain.
Leave a Reply
Your Comment is awaiting moderation.